Clinical Trial Update: Open-label Study to Investigate Systemic Exposure in Adult and Pediatric Atopic Dermatitis Patients Treated 8.5 Days With Pimecrolimus Cream 1% Under Occlusion [Phase 4]

View source ↗

Summary

Open-label Phase 4 study assessing systemic exposure of pimecrolimus cream 1% under occlusion in adult and pediatric atopic dermatitis patients; study completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Pimecrolimus Cream 1% (pimecrolimus)

Snippet

Sponsor: Novartis | Conditions: Atopic Dermatitis | Phase 4 | Status: COMPLETED